Clinical Trial Update: Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial update of afatinib alone or in combination with vinorelbine in HER2-positive breast cancer with brain metastases; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Breast Cancer

Drugs mentioned

• Gilotrif (Afatinib)
• Navelbine (vinorelbine)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Breast Neoplasms, Neoplasm Metastasis | Phase 2 | Status: COMPLETED | Results posted: 2015-02-25